Plan-les-Ouates, Switzerland
Plan-les-Ouates, Switzerland

Time filter

Source Type

La plateforme exclusive SUREtechnology de Selexis facilite la production rapide, stable et rentable de presque toutes les protéines recombinantes et permet une intégration en souplesse du continuum de développement dans le domaine de la biologie et de la vaccination, de la découverte à la commercialisation. « Les technologies de Selexis sont novatrices et agiles. Nous nous adaptons aux besoins des sociétés biopharmaceutiques mondiales en prévoyant de réaliser de robustes projets qui ciblent plusieurs domaines thérapeutiques et divers modes de développement de médicaments et vaccins, », a fait savoir Igor Fisch, PhD, président du Conseil d’administration et président directeur-général de Selexis. « Nous offrons une solution à guichet unique à nos partenaires, et ce modèle est validé par l’accroissement continu de nos collaborations, dont plusieurs sont à long terme tandis que ces sociétés font progresser leurs candidats tout au long du processus de développement clinique et jusqu’à la fabrication des produits biologiques et vaccins. » Selexis SA est une société pionnière dans le domaine des sciences de la vie et un leader mondial dans la production de lignées cellulaires de mammifères (suspension-adapted CHO-K1), proposant une technologie brevetée unique et l’expertise hautement spécialisée nécessaire pour transformer l’innovation scientifique en médicaments pour les patients qui sauvent des vies. La plateforme SUREtechnology ™ de Selexis facilite la production rapide, stable et rentable de presque toutes les protéines recombinantes et permet une intégration en souplesse du continuum de bioproduction, de la découverte à la commercialisation. Avec plus de 95 partenaires dans le monde, près de 80 produits pharmaceutiques en fabrication clinique et deux produits commerciaux utilisant ses lignées cellulaires, Selexis a pour mission de permettre aux scientifiques et aux sociétés biopharmaceutiques du monde entier de réaliser le plein potentiel de leurs recherches. Pour plus d’informations, visitez le site www.selexis.com.


News Article | February 21, 2017
Site: www.businesswire.com

GENEVA--(BUSINESS WIRE)--Selexis SA announced today it has entered three service agreements with Sanofi, through which Selexis will develop research cell banks using its SUREtechnology Platform. Under the three agreements, Selexis will develop: “Our SUREtechnology Platform provides an option that biopharmaceutical companies may consider for developing both biologics and vaccine treatments,” said Marco Bocci, PhD, DPharm, Selexis vice president, licensing and business development. “It’s rewarding to work with Sanofi across multiple applications including vaccines.” Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization. “Selexis’ technologies are innovative and nimble. We adapt to the required needs of global biopharmaceutical companies with robust pipelines targeting multiple therapeutic areas and various modes of drug and vaccine development,” said Igor Fisch, PhD, Selexis chairman and chief executive officer. “We offer a one-stop solution to our partners, and this model is validated by the continued expansion of our collaborations, many of which are long-term relationships as these companies advance their candidates through the clinical development process to biologics and vaccine manufacturing.” Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, nearly 80 drug products in clinical manufacturing and two commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.


News Article | February 21, 2017
Site: www.businesswire.com

Selexis SA è una società pionieristica nel settore delle scienze della vita e un leader globale nella produzione di linee cellulari di mammifero (CHO-K1 adattate alla sospensione), grazie all'esclusiva tecnologia proprietaria e all'esperienza altamente specializzata necessaria per tradurre l'innovazione scientifica in farmaci che salvano la vita dei pazienti. La SUREtechnology Platform™ di Selexis facilita la produzione rapida, stabile ed economica di praticamente qualsiasi proteina ricombinante, offrendo un'integrazione ininterrotta della produzione continua di prodotti biofarmaceutici, dalla scoperta alla commercializzazione. Con oltre 95 collaboratori a livello globale, circa 80 prodotti farmaceutici in produzione clinica e due prodotti commerciali che utilizzano le proprie linee cellulari, Selexis è rinomata per la sua offerta a scienziati e società biofarmaceutiche in tutto il mondo di realizzare le piene potenzialità della propria ricerca. Per maggiori informazioni, visitare www.selexis.com.


News Article | February 21, 2017
Site: www.businesswire.com

Selexis SA ist ein wegbereitendes Life-Sciences-Unternehmen und weltweit führend bei der Herstellung von Säugetierzelllinien (in Suspension adaptierte CHO-K1). Es bietet einzigartige proprietäre Technologie und hochspezialisierte Fachkenntnisse, die erforderlich sind, um wissenschaftliche Innovation in lebensrettende Medikamente für Patienten umzusetzen. Die SUREtechnology Platform™ von Selexis ermöglicht die rasche, stabile und kostengünstige Herstellung praktisch aller rekombinanten Proteine und bietet die nahtlose Integration des Bioproduktionskontinuums, von der Entdeckung bis zur Vermarktung. Mit weltweit mehr als 95 Partnern, fast 80 Arzneimittelprodukten in der klinischen Herstellung und zwei kommerziellen Produkten, bei denen die Zelllinien des Unternehmens zum Einsatz kommen, versetzt Selexis Wissenschaftler und biopharmazeutische Unternehmen in der ganzen Welt seit jeher in die Lage, das volle Potenzial ihrer Forschung auszuschöpfen. Weitere Informationen finden Sie unter www.selexis.com.


A purified and isolated DNA sequence has protein production increasing activity. Said DNA sequence comprises at least one bent DNA element, and at least one binding site for a DNA binding protein. It is a MAR nucleotide with the sequence SEQ ID No 24, a sequence complementary thereof, or a sequence having at least 70% identity with said sequence. Advantageously the bent DNA element contains at least 10% of dinucleotide TA, and/or at least 12% of dinucleotide AT on a stretch of 100 contiguous base pairs.


A purified and isolated DNA sequence has protein production increasing activity. Said DNA sequence comprises at least one bent DNA element, and at least one binding site for a DNA binding protein. It is a MAR nucleotide with the sequence SEQ lD No 27, a sequence complementary thereof, or a sequence having at least 70% identity with said sequence. Advantageously the bent DNA element contains at least 10% of dinucleotide TA, and/or at least 12% of dinucleotide AT on a stretch of 100 contiguous base pairs.


A purified and isolated DNA sequence has protein production increasing activity. Said DNA sequence comprises at least one bent DNA element, and at least one binding site for a DNA binding protein. It is a MAR nucleotide with the sequence SEQ ID No 26, a sequence complementary thereof, or a sequence having at least 70% identity with said sequence. Advantageously the bent DNA element contains at least 10% of dinucleotide TA, and/or at least 12% of dinucleotide AT on a stretch of 100 contiguous base pairs.


The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.


Patent
Selexis S.A. | Date: 2014-02-01

Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.


News Article | February 21, 2017
Site: www.businesswire.com

Selexis SA is een baanbrekend life sciences bedrijf en een wereldleider op het gebied van de generatie van (voor suspensie aangepaste CHO-K1) zoogdiercellijnen en biedt ongeëvenaarde bedrijfseigen technologie en de zeer gespecialiseerde expertise die nodig is om wetenschappelijke innovatie te vertalen naar levensreddende geneesmiddelen voor patiënten. Selexis’ SUREtechnology Platform™ vergemakkelijkt de snelle, stabiele en kosteneffectieve productie van vrijwel elk recombinant eiwit en zorgt voor een naadloze integratie van het ontwikkelingscontinuüm voor biologics en vaccins, van ontdekking tot commercialisering. Met meer dan 95 partners wereldwijd, bijna 80 geneesmiddelen in klinische productie en twee commerciële producten die gebruik maken van haar cellijnen, heeft Selexis een geschiedenis van ondersteunen van wetenschappers en biofarmaceutische bedrijven over de hele wereld om het volledige potentieel van hun onderzoek te realiseren. Meer informatie is beschikbaar op www.selexis.com. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Loading Selexis SA collaborators
Loading Selexis SA collaborators